Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CIR-NA in Healthy and Prediabetic Subjects
NCT06378125Phase 1Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of controlled-ileal-release nicotinic acid in prediabetes (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Treatment-Emergent Adverse Events up to 60 days, Treatment-Emergent Serious Adverse Events up to 60 days and 9 more. Started Dec 2022; status: completed.
02
Drugs
controlled-ileal-release nicotinic acid
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT06378125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378125.